Impact of baseline hepatitis B virus viral load on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy

Table 2 Tumor response between the hepatitis B virus-DNA ≤ 2000 and hepatitis B virus-DNA > 2000 groups, n (%)

	RECIST 1.1		P value	mRECIST		P value
	HBV ≤ 2000, n = 66	HBV > 2000, n = 54		HBV ≤ 2000, n = 66	HBV > 2000, n = 54
CR	0	0	-	0	0	-
PR	13 (19.70)	17 (31.48)	0.14	15 (22.73)	18 (33.33)	0.20
SD	35 (53.03)	21 (38.89)	0.12	37 (56.06)	23 (42.59)	0.14
PD	18 (27.27)	16 (29.63)	0.78	14 (21.21)	13 (24.07)	0.71
ORR	13 (19.70)	18 (33.33)	0.09	15 (22.73)	22 (40.74)	0.03
DCR	48 (72.73)	40 (74.07)	0.87	52 (78.79)	41 (75.93)	0.71

Data in brackets represent the percentages of patients. HBV: Hepatitis B virus; CR: Complete responds; PR: Partial responds; SD: Stable disease; PD: Progression disease; ORR: Objective responds rates; DCR: Disease control rates.